THE UNIVERSITY OF BRITISH COLUMBIA

CURRICULUM VITAE
Updated January 14, 2025

FACULTY OF Medicine
DEPARTMENT Medicine

I. BIOGRAPHICAL DATA

Name: Dr. Donald A. Cameron

Present Rank: Neurologist

Place of Birth: London, Ontario Canada

Date of Birth: June 28, 1952 Sex: Male

Citizenship: Canadian Marital Status: M

Children: Two

II. EDUCATION

a. Undergraduate:
   i. University of Guelph Chemistry Sept. 1972 – May 1977 B.Sc. (Hon.)

   ii. Queen's University Sept. 1978 – May 1982 M.D.

b. Special Professional:
   i. Internship – Straight Internal Medicine, UBC

   ii. Residency – Internal Medicine 1984

   iii. Residency – Neurology 1983, 1985 – 1987

   iv. Fellow Royal College of Physicians and Surgeons of Canada November 1990 in Neurology

c. Graduate:
   Not applicable

d. Titles of theses written for graduate degrees:
Not applicable

III. ACADEMIC AWARDS and DISTINCTIONS

a. Member, Canadian Stroke Advisory Council

b. Member, Canadian Society of Clinical Neurophysiologists, area of specialty in Electroencephalography, June 1996, Electrodiasnostic studies June 1990.

c. Qualification in Electromyography and Electroencephalography, March 1990.

d. MRC Post Doctoral Fellowship. The Study of Positron Emission Tomography and Its Application to Cerebrovascular Disease.

e. North American Symptomatic Carotid Endarterectomy Trial. Vancouver Centre Co-principal Investigator, July 1987 – July 1989

f. MRC Summer Scholarship 1979.

g. Physicians and Surgeons Institute of Ontario Summer Clinical Scholarship

IV. PROFESSIONAL EMPLOYMENT RECORD

a. Teaching, Professional or Research Positions Held Prior to U.B.C. Appointment:

    i. Post Doctoral Fellow at U.B.C. listed under Academic Awards and Distinctions

b. Date of first appointment at the University of British Columbia, May 13, 1991
Rank Associate Member, Clinical Instructor

c. Subsequent ranks including dates of promotion:
Not applicable

d. Date of Granting of Appointment without Term:
Not applicable

e. Principal University and Department Teaching and Service Responsibilities Over the Last Five Years:

   i. As a neurology resident and as a Post Doctoral Fellow involved in teaching interns, residents, and medical students at Lion's Gate Hospital on a daily basis, in office teaching residents and medical students several times yearly for up to one or two week intervals

f. Record of leaves of absence:
Not applicable

V. PROFESSIONAL ACTIVITIES

a. Membership in Professional and Learned Societies:

   i. British Columbia Medical Association

   ii. Canadian Medical Association

   iii. Canadian Neurological Society

   iv. American Academy of Neurology

   v. Fellow of The Stroke Council, American Heart Association

   vi. Fellow American Neurological Association

   vii. American Epilepsy Society

   viii. American College of Physicians

   ix. Amyotrophic Lateral Sclerosis Society, Member Board of Directors, British Columbia Section 1989-1995

   x. Head, Division of Neurology, Department of Medicine, Lion's Gate Hospital, January 1977- July 1, 2017, Member, Division of Neurology, Lions Gate Hospital

   xi. Clinical Director, Lion's Gate Hospital Rehabilitation Team

   xii. Director, Neurology and Neurosurgery Special Intensive Care Unit, Lion's Gate Hospital 1992-1995

xiii. Member New York Academy of Sciences 1994-1996

xiv. Director, Electroencephalography laboratory Lions Gate Hospital January 1995-June 2018.

xiv. Critical Care Committee, Lion's Gate Hospital, 1993-1995

xv. Past Member Executive Committee, Medical Legal Society of British Columbia

xvi. Member, Canadian Society of Clinical Neurophysiologists, specialty in Electroencephalography and Electrodiagnostic Studies

xvii. Charter Member, Medical Research Council of Canada

xviii. Past Member, Canadian Stroke Advisory Council

xix. Past Member, Vancouver Regional Stroke Planning Committee

xx. First Chairperson and Current Member, Ethics Committee, Canadian Stroke Consortium

xxi. Member, Policy and Advocacy Committee, Canadian Stroke Consortium

xxii. Investigator, Neurology Clinical Practices, College of Physicians and surgeons of British Columbia. Appointed in 2018

b. Academic or Professional Awards and Distinctions:

i. Qualification in Electroencephalography, August 1991

ii. Qualification in Electrodiagnostic Studies and Electromyography, July 1990

c. Professional Service and Experience:

i. Rabies Encephalomyelitis: A Case Study. IX Annual BC Neuroscience Academic Day, March 1986.

ii. Discussion of the Risk Factors of Stroke. West Vancouver Community Centre, September 18, 1987.

iii. Pseudotumor Cerebri and Cerebral Dural Sinus Thrombosis; A Rare Complication of the Anticardiolipin Syndrome. The Arthritis Society of BC and the Yukon Research Day, November 20, 1987.

iv. Discussion of Stroke and its Prevention. Vancouver, Golden Age Club, December 1987.

v. Parkinson's Disease: The Role of the Family. Vancouver Neurological Centre, March 16, 1987

vi. The Investigation of Symptomatic Carotid Stenosis. The Role of Cerebral Angiogram vs. Carotid Ultrasound and Discussion of the North American Symptomatic Carotid Endarterectomy Trial. XXII Annual BC Neuroscience Academic Day, March 3, 1989.

vii. The North American Symptomatic Carotid Endarterectomy Trial; An Update and Discussion. West Coast Vascular Society Conference, April 30, 1989.

viii. Treatment of Parkinson's Disease; Kelowna, B.C., May 21, 1989.

ix. Current Therapy of Parkinson's Disease, McMaster University, Hamilton, Ontario, August 25, 1992.

x. Parkinson's Disease, Epidemiology and Therapy: Parksville, B.C., November 9, 1992.

xi. Migraine, Epidemiology and Treatment Strategies: Lion's Gate Hospital, North Vancouver, B.C., December 14, 1992.

xii. Stroke, Epidemiology and Current Therapy: Grand Rounds, Lion's Gate Hospital, North Vancouver, B.C., December 15, 1992.

xiii. Migraine, Epidemiology and Prophylactic Treatment Strategy. Grand Rounds, Langley Memorial Hospital, Langley, B.C., January 21, 1993.

xiv. Controversies in Stroke Management. Seminar Series, Chilliwack, B.C., October 19, 1993.

xv. Parkinson's Disease, Current Therapy. Kelowna, B.C., November 17, 1993.

xvi. An Update in Neurology, Grand Rounds, Lion's Gate Hospital, North Vancouver, B.C., January 11, 1994.

xvii. Strategies in Treatment of Stroke, Grand Rounds, Langley General Hospital, Langley, B.C., March 3, 1994.

xviii. Ischemic Stroke, Treatment in 1994, Grand Rounds, Abbotsford General Hospital, March 9, 1994.

xix. Ischemic Stroke Therapeutic Possibilities, Vancouver, B.C., October 4, 1994.

xx. Acute Stroke Therapy of Ischemia. Chilliwack, B.C., October 5, 1994.

xxi. Parkinson's Disease, An Update, Grand Rounds, Lion's Gate Hospital, North Vancouver, B.C., November 29, 1994.

xxii. Stroke Update 1996; North Vancouver, February 8, 1996.

xxiii. New Therapy in Cerebrovascular Disease; Grand Rounds, Burnaby General Hospital, June 1996.

xxiv. Acute Stroke Therapy; Canadian Association of Neurological Nurses, November 28, 1996.

xxv. Role of rt-PA in The Treatment of Stroke. Journal Club, Emergency Physicians, Lion's Gate Hospital, January 22, 1997.

xxvi. Update in Treatment of Parkinson's Disease; Grand Rounds, Lion's Gate Hospital, May 2, 1998.

xxvii. Stroke Update 2001; Grand Rounds, Lion's Gate Hospital, March 2001.

xxviii. Migraine: A Case Study. Interactive Workshop, May 24, 2001.

xxix. Transient Ischemic Attack an Update of Therapy and Regional Referral Pattern Policy. St. Mary's Hospital Grand Rounds, Sechelt, BC June 10, 2010

xxx. Transient Ischemic Attack an Update of Therapy and Regional Referral Pattern Policy, Squamish General Hospital, Squamish, BC December 3, 2010.

xxxi. Transient Ischemic Attack an Update of Therapy and Regional Referral Pattern Policy. Whistler Health Care Clinic, Whistler, BC January 21, 2011.

xxxii. Transient Ischemic Attack an Update of Therapy and Regional Referral Pattern Policy. Powell River Regional Hospital, Powell River, BC March 18, 2011.

xxxiii. Transient Ischemic Attack an Update of Therapy and Referral Pattern and Update, St. Mary's Hospital, Sechelt, BC June 10, 2011.

xxxiv. Stroke Update 2014; Grand Rounds, Lions Gate Hospital, March 2014.

xxxv. Stroke Update December 3, 2015, Grand Rounds, Lion's Gate Hospital.

xxxvi. Co-chairperson, Trial lawyers Association of BC Conference May 5-6, 2017.

xxxvii. Current understanding of Traumatic Brain Injury Physiology +latest pharmacological Advances May 5, 2017, Trial Lawyer Assoc. of BC conference.

VI. RESEARCH and PROFESSIONALLY-RELATED SCHOLARLY and CREATIVE ACTIVITIES

a. Areas of Special Interest and Accomplishment in Discipline:

i. Expert Witness, Supreme Court of British Columbia, in the field of Neurology since 1992.

ii. Expert Witness, Superior Court of Washington State

iii. Expert Witness, Supreme Court of New Brunswick.

iv. Expert Witness, Supreme Court of Ontario

v. Motor Neuron Disease

vi. Multiple Sclerosis – past involvement as a clinical investigator in a drug study for patients suffering with MS.

vii. Canadian Society of Clinical Neurophysiology (CSCN) in Electroencephalography, Electromyography

viii. Cerebrovascular Disease – two year Medical Research Council of Canada (MRC) Post Doctoral Fellowship in Stroke Research. Fellow of the American Heart Association (FAHA). Stroke Neurologist.

ix. Extrapyramidal diseases. Providing botulinum toxin therapy for movement disorders since 1990.

x. Principle Investigator, Vancouver Centre, in the North American Randomized Acute Therapy for Ischemic Stroke. (RANTTAS) 1992-1995.

xi. Principle Investigator, "Stroke Treatment with Ancrod (Arvin) Trial," Jan 1997-Jan 1998.

xii. Principle Investigator, "Cerestat (aptiganel Hydrochloride) in Acute Ischemic Stroke," Jan 1997-Dec. 1997

xiii. Principle Investigator "Bay x 3702", in Acute Ischaemic Stroke, Oct. 31-Jan. 1998.

xiv. Principle Investigator, CLASS "Clomethiazole" in Acute Ischaemic Stroke, Feb. 1998-Dec. 1998.

xv. Principle Investigator for CANADA, ICOS International Stroke Clinical Trial (AST02), February 1999-2004.

xvi. Principle Investigator, Lion's Gate Hospital, Acute Stroke Therapy with Repinotan Hydrochloride, Jan-May 2001.

xvii. Principle Investigator, Lion's Gate Hospital, Acute Stroke Therapy with UK-279,276 (ASTIN), Jan. 2001-2004.

xviii. Co-Principle Investigator, Lion's Gate Hospital, Oral Thrombin Inhibition (SH-TPA-0005) vs. Warfarin. May 2001-2004.

xix. Member Canadian Stroke Consortium 1995-present.

xx. Regional Director, Canadian Stroke Consortium, 1996-present.

xxi. Migraine Headache – Past investigator in an International Migraine Quality of Life Clinical Study, and "A Study to Evaluate S/C Sumatriptan in Patients Who Have Not Responded to Oral Tablets"

xxii. Investigator evaluating quality of life in patients using Sumatriptan Nasal Spray in treatment of Migraine Headache.

xxiii. Parkinson's Disease

b. Research or Equivalent Grants Received as Principal Investigator:

i. Principle Investigator – RANTTAS – Randomized Trial of Tirilazad in Patients with Acute Stroke, funded by NIH; April 1993

ii. Principle Investigator – An Observational Prospective Study to Evaluate the Impact of Subcutaneous Sumatriptan as an acute Migraine Therapy of Economic Costs and Quality of Life, May 1993

iii. Principle Investigator – A Study to Evaluate S/C Sumatriptan in Patients who have not responded to oral tablets.

iv. Principle Investigator – Use of Cerestat in the Treatment of Acute Stroke

v. Principle Investigator – Use of Ancrod in the Treatment of Acute Stroke.

vi. Investigator – Evaluating Quality of Life in Patients Using Lamotrigine in the Treatment of Epilepsy.

vii. Investigator – Evaluating Quality of Life in Patients Using Sumatriptan Nasal Spray for Treatment of Migraine.

viii. Principle Investigator for Canada. ICOS International Acute Stroke Clinical Trial (AST02)

ix. Principle Investigator, Lion's Gate Hospital. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Effects of a Targeted Exposure of Intravenous Repinotan in Patients with Acute Ischemic Stroke. Jan-May 2001.

x. Principle Investigator, Lion's Gate Hospital. Multicentre, randomized, double-blind, two arm, parallel group study of SH-TPA-0005(H376/950) vs. dose-adjusted warfarin. May 2001-2004.

c. Theses supervised: Not applicable

VII. OTHER RELEVANT INFORMATION

a. Licence/Registrations:

i. Medical Council of Canada, Dec. 1990

ii. College of Physicians and Surgeons of BC, Dec. 1990

iii. College of Physicians and Surgeons of Ontario, May 1991

b. Hospital Affiliations:

i. Lions Gate Hospital – Consultant Staff
ii. Member Division of Neurology, Dept. of Medicine UBC

THE UNIVERSITY OF BRITISH COLUMBIA

PUBLICATIONS RECORD

NAME IN FULL: Cameron, Donald Alexander

FACULTY: Medicine
DEPARTMENT OR SCHOOL: Medicine

Refereed Publications:

1. Kokesh F, Cameron DA, Kakuta Y, Kuras FV. Hydrolysis of D-glycopyranose 1, 2 cyclic phosphate. The Effect of pH and Temperature on the Product Distribution and the Position of Opening of the Phosphate Diester Ring in Formation of D-glucose 2-phosphate. Carbohydrate Research 62:289-300, 1978.

2. Nakatsu K, Cameron DA. Uptake of Liposome-Entrapped Mannitol by Diaphragm. Canadian Journal of Physiology and Pharmacology 57(7):7560759, 1979.

3. Riopelle RJ, Cameron DA. Neurite Growth Promoting Factors of Embryonic Chick Ontogeny, Regional Distribution and Characteristics. Journal of Neurobiology 12:175-186, 1981.

4. Riopelle RJ, Boegman RJ, Cameron DA. Peripheral Nerve Segments Promote Neurite Outgrowth from Embryonic Sensory and Spinal Cord Neurons In Vitro. Neuroscience Letters 25(3):311-316, September 25, 1986.

5. Riopelle RJ, Cameron DA. Neurite-Promoting Factors from Embryonic Neurons. Brian Research 317(2):265-274, August 1984.

6. Barnett HJM, et al NASCET Study Group. Beneficial Effect of Carotid Endarterectomy in Symptomatic Patients with High-Grade Stenosis. N Engl J Med 1991: 325:445-53

7. Eisen AE, Cameron DA. Amyotrophic Lateral Sclerosis: Some Current Views. Neurologic Clinics of North America. December 1992.

8. Sibley et al, The IFNB Multiple Sclerosis Study Group. Interferon Beta – 1B is Effective in Relapsing – Remitting Multiple Sclerosis. Results of a Multicenter, Randomized, Double-Blind, Placebo Controlled Trial. Neurology 1993, Vol. 43, pp655-661.

9. Eisen AE, Cameron DA, Schulzer M, Stewart H, Anti-Glutamate Therapy in Amyotrophic Lateral Sclerosis: A Trial Using Lamotrigine. Can J Neurol Sci 1993;20:297-301.

10. Andrei V. Alexandrov et al, Agreement on Disease-Specific Criteria for Do-Not-Resuscitate Orders in Acute Stroke. Stroke Vol 27 #2 pp232-237, Feb 1996.

11. The RANTTAS Investigators. A Randomized Trial of Tirilazad Mesylate in Patients with Acute Stroke (RANTTAS). Stroke, Vol 27 (9), 001453-1458, 1996.

12. Consensus Against Both Endarterectomy and Routine Screening for Asymptomatic Carotid Artery Stenosis. J. R. Perry et al. Archives of Neurology, Jan. 1997, Vol 54, pp 25-28.

13. Johnston, K.C. et al. Medical and Neurological Complications of Ischemic Stroke. Experience from the RANTTAS Trial. Stroke, Vol 29 (1) pp 447-453.

14. Saver, J.L. et al for the RANTTAS Investigators. Infarct Volume as a Surrogate or Auxiliary Outcome Measure in Ischemic Stroke Clinical Trials. Stroke Vol 30:293-298, 1999.

15. Intravenous Ancrod for Treatment of Acute Ischemic Stroke. The STAT Study: A Randomized Controlled Trial. Sherman, D. G. et al.

16. Cameron, D.A., Cristurean, P. Predictive value regarding neurological outcome following spinal surgery utilizing pre-operative baseline intra-operative, and post-operative somatosensory Evoked Potential Electrophysiological Monitoring Data. Submitted for publication Journal of Clinical Neurophysiology, May 2021.

REFEREED ABSTRACTS

1. Riopelle RJ, Cameron DA. Neurite Outgrowth Activity in Soluble Extracts of Chick Ontogeny and Embryonic Day 8 Regional Distribution. Society Neurosci Abstracts 770, 1979.

2. Riopelle RJ, Cameron DA. Ontogeny and Regional Distribution of Neurite, Outgrowth Factors in Embryonic Chick. Abstracts of the XIVth Canadian Contress of Neurological Sciences, Can J Neurological Sci 6:395, 1979.

3. Riopelle RJ, Boegman RJ, Cameron DA. Peripheral Nerve Segments Promote Neurite Outgrowth from Embryonic Sensory and Spinal Cord Neurons In Vitro. Abstracts of the XVth Canadian Congress of Neurological Sciences, Can J Neurological Sci 7:322, 1980.

4. Riopelle RJ, Cameron DA. Neuronal Autostimulation – Evidence for Trophic Factors and Substrate – Attached material produced by neuron-enriched cultures. Abstracts of the XVIth Canadian Congress of Neurological Sciences, Can Neurological Sci 8, 1981.

5. Cameron, DA, et al. Rabies Encephalomyelitis Treated with Interferon. Abstracts of the XXIst Canadian Congress of Neurological Sciences, Can J Neurological Sci 13:178, 1986.

6. Cameron DA, Calne DB. Parkinson’s Disease, Treatment with Deprenyl. Abstracts of the XXIst Canadian Congress of Neurological Sciences, Can J Neurological Sci 13:175m 1986.

7. Cameron DA, et al. Macrogyria in Intractable Seizures. American Epilepsy Society Proceeding, November 1986, Epilepsia (5):594, 1986.

8. Cameron DA, et al. Therapeutic Trial of Glutamate Inhibition in Amytrophic Lateral Sclerosis Using Lamotrigine. Abstracts of the XXVIIth Canadian Congress of Neurological Sciences, Can. J. Neurological Sci 20, Supplement 2, pS8.

9. Eisen AE, Cameron DA, Schulzer M, Sterwart H, Anti-Glutamate Therapy in Amyotrophic Lateral Sclerosis: A trial using Lamotrigine. International Abstracts, Neurology, Nov/Dec 1993.

10. The RANTTAS Investigators. The Neuroclinical Trials Center, University of Virginia, Charlottesville VA. and the North American RANTTAS participants. Randomized Trial of Tirilazad in Acute Stroke (RANTTAS). Stroke Vol 27, 1, Jan. 1996, pp195.

11. Cameron DA, Black SE. Stroke Treatment with Ancrod Trial. The Canadian Journal of Neurological Sciences, Vol 8, 5, Suppl. 1 – s164, 1998.

12. Sherman, D.G. et al. Defibrinogenation with Viprinex (Ancrod) for the Treatment of Acute Ischemic Stroke. Stroke, page 234, 1999.

13. Chan, M.T.Y., Nadareishvili Z. and the Canadian Stroke Consortium. Diagnostic Strategies in Young Stroke Patients. Annals of Neurology, Vol 44, No.3 Sept 1998, M19.

14. Cameron, D. A.. Benign Essential Rotational Head Tremor? The Importance of the Clinical Examination. The Canadian Botulinum Toxin Neurologists Conference, Newport Beach Calif. Jan 28-30, 2010.

15. Alpha FIM: Implementation of Utilization of a Functional Independence Measure (FIM) Tool for Acute Stroke Patients. Sandra Broughton, MSN, D.A. Cameron, BSc (Hon) MD FRCPC F.A.H.A., Marlene Legend, OT, Colleen Von Hoof, PT, Mia Masters, ScP, Cindy Huntley, RN. Canadian Stroke Congress, Vancouver, BC October 2014

16. Stroke Patient Journey in British Columbia; Rural and Coastal Communities; Transportation Algorithms within Vancouver Coastal Health. D.A. Cameron BSc (Hon) M.D. FRCP(C) F.A.H.A. Manieve Legirand, Canadian Stroke Congress September 14-16, 2016

17. Cameron, D.A., Cristurean, P. Predictive value regarding neurological outcome following spinal surgery utilizing pre-operative baseline intra-operative, and

post-operative somatosensory Evoked Potential Electrophysiological Monitoring Data. Accepted presentation Annual General Meeting American Neurological Association (ANA). October 17-19, 2021.